A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors
Status:
Completed
Trial end date:
2000-10-01
Target enrollment:
Participant gender:
Summary
This study examines a 96 hour infusion schedule of irinotecan alternating with 72 hour
drug-free intervals in patients with solid tumors in order to determine the maximum tolerated
dose of this regimen.